Podcasts about Toga

Rob and MJ talked all things Belmont with Matthew DeSantis from NYRA Bets!

Rob and MJ talked again with the great Andy Serling from NYRA and FOX Sports!

Rob and MJ talked all things Belmont with Saratoga County Chamber of Commerce President Todd Shimkus!

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide, leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer. Joined by Prof Ahn Myung-ju, a Medical Oncologist at Hanyang University Medical Centre in South Korea as well as Co-chair for the upcoming World Lung Cancer Conference, and A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital in Sydney. The panel discusses the clinical characteristics and incidence of this molecular subset, the critical need for upfront comprehensive genomic testing, key clinical trial data for targeted therapies, and practical strategies for managing treatment-specific side effects like pyrexia syndrome. This episode is sponsored by Pierre Fabre.   (00:00) Welcome and Acknowledgement (00:47) Introducing the Topic and Panel (01:56) BRAF Incidence Overview (02:43) Testing Pathways in Australia (06:16) Mutation Classes and Tools (07:47) Korea Testing Perspective (09:03) Pivotal Targeted Therapy Trials (13:33) Choosing First Line Treatment (16:40) Australian Sequencing Approach (20:23) Managing Pyrexia and Toxicities (25:49) Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

The crew is back for episode 131 and TY opens the show by declaring war on Luka Doncic (yes, really). From there it's a packed one: the Obsession horror movie spoiler breakdown, the NBA Finals matchup between the Knicks and Spurs, Sony's State of Play, the new God of War reveal, plus heavy anime discussion across Blue Lock, Witch Hat Atelier, Daemons of the Shadow Realm, and Re:Zero Season 3.SPOILER ZONE: Obsession (2026) full breakdown starts early. Skip ahead if you haven't seen it.What we get into:Naming the craziest female anime villains better than Nikki from Obsession (Yuno Gasai, Shiro from Deadman Wonderland, the full Kakegurui lineup, Toga, Makima, Priscilla, and more)Is Nikki actually the villain of Obsession, or is Bear the real problem? The Ian debate gets heatedSarah's death scene, the diner moment, the One Wish Willow rules, and that ending sequenceBest horror performances of the 21st century: Toni Collette, Bill Skarsgård, Lupita Nyong'o, William Dafoe, James McAvoy, and Andy Navarro's case for the listHorror Movie King of the Hill: Obsession vs Get Out, Hereditary, Midsommar, Insidious, Conjuring, Sinners, Paranormal Activity, and Talk to MeWishes the crew would make to fix anime: Reborn pacing, Gintama actually being funny, Promised Neverland Season 2 erased, Future Trunks staying in the main timeline, the Black Clover finale Asta vs Yuno fight, and Berserk going to MAPPABlue Lock chapter reactions: is Ego's philosophy actually wrong? The Isagi vs Hugo aftermath and what comes nextWitch Hat Atelier: Kifri going too far, the Brimcap mystery, Coco and Tartar's growing dynamic, plus a real talk comparison between magic gatekeeping and AI regulationDaemons of the Shadow Realm: who's the Kagamori traitor (Bald Guy slander incoming), Yuru's future, and the grandma agendaRe:Zero Season 3: amnesia Subaru crash out hype, the staircase scene anticipationNBA Finals predictions: Knicks vs Spurs, the Cat factor, how Brunson handles Stephon Castle and Dylan Harper, and whether NYC actually wilds out if the Knicks winNFL chaos: Rams trading for Myles Garrett (Aaron Donald comeback talk), Patriots landing AJ Brown, and which playoff teams are dropping out next seasonSony State of Play reactions: Marvel's Wolverine, Onimusha, Tomb Raider, and the new God of War starring Kratos' wife (DLC energy or worth the slot?)Wuthering Heights debate: Margot Robbie's performance and Radell holds the line on his original takePlus, the crew is two episodes deep on the Game of Thrones Season 8 Patreon rewatch, House of the Dragon Season 3 watch party prep, and a Mask vs Mask WWE match getting flowers.If you mess with anime debates, horror movie takes, NBA discourse, and gaming reactions all in one place, lock in.KEYWORDS (SEO-loaded for podcast platforms and YouTube):Black Sensei Society, BSS podcast, anime podcast, Obsession movie review, Obsession 2026 spoilers, Andy Navarro Obsession, best horror movies of 2026, horror movie king of the hill, best horror performances 21st century, Yuno Gasai, Kakegurui, Makima, anime villainess tier list, Blue Lock chapter review, Ego philosophy Blue Lock, Isagi vs Hugo, Witch Hat Atelier review, Kifri Coco Tartar, Daemons of the Shadow Realm, Re:Zero Season 3, Subaru amnesia arc, NBA Finals 2026, Knicks vs Spurs prediction, Jalen Brunson, Victor Wembanyama, Stephon Castle, Karl Anthony Towns, Myles Garrett trade, Rams Super Bowl, Patriots AJ Brown, Sony State of Play, Marvel's Wolverine, new God of War 2027, Kratos wife game, Onimusha Way of the Sword, Tomb Raider, Wuthering Heights Margot Robbie, anime debate podcast, manga podcast, sports and anime podcast, Black podcastershttps://linktr.ee/blacksenseisociety

On this edition of the podcast Eric is joined by Houston BBQ Festival co-founder Michael Fulmer. Since the news edition of the podcast has been off for a couple of weeks, the duo catch up on some of the biggest news from the Houston culinary scene including Betelgeuse Betelgeuse owner Chris Cusack getting arrested for health code violations, Mack McDonald getting set to open a new steakhouse concept, and Bludorn Hospitality's latest endeavor - a mystery concept in San Antonio. In the Restaurants of the Week portion, Toga and Sip & Skewer are featured.Got a question for Eric? Email him at eric@culturemap.com. Follow Eric on Instagram @ericsandler and check out some of Eric's latest articles online at Culturemap.com: Houston Bar Owner Speaks Out About Surprise Arrest for Health Code Violations Houston Restaurateur Steps Up with Massive River Oaks-Area Steakhouse Texas Comfort Food Restaurant Closes at Memorial City After 10 Years Chris Shepherd's TV Show Eat Like a Local Ends its Run After 3 Years Croissant-Obsessed French Cafe Sets Opening Date in Downtown Houston Park

Ovaj video objašnjava kako tvoja slika o sebi oblikuje sve što doživljavaš u životu i zašto se pravi napredak počinje tek kada promijeniš način na koji vidiš sebe.

„Błędy młodego mecenasa” - trzeci odcinek podcastu „Toga bez wroga”, do którego serdecznie zapraszam. To takie mało popularne, takie nieprawnicze, powiedzieć „popełniłem mnóstwo błędów w tej robocie”. Prawnicy nie popełniają błędów! This is Sparta… and we are the champions. Dlatego też dziś śmiało mogę napisać… Popełniłem, przez 18 lat, mnóstwo błędów w tej robocie. I cieszy mnie to… Dlaczego cieszy? Posłuchaj podcastu. Marshall Rosenberg, wspaniały człowiek uczący komunikacji bez przemocy (nonviolent communication) napisał: „Nie ma czegoś takiego jak błędy. Błąd to nic innego tylko działanie, które podjęliśmy kiedyś, ponieważ nie wiedzieliśmy tego, co wiemy dziś”. Tym razem w podcaście szczerze dzielę się błędami, które popełniłem na zawodowej ścieżce :) Wróć! Nie błędami, a doświadczeniami, które sprawiają, że jestem tu gdzie jestem i robię to, co kocham robić. Na pewno odnajdziesz w mojej historii kawałek swojego prawniczego życia. Te błędy, to nie tylko „moje” doświadczenia. Na każdej sesji, któryś z tych błędów pojawia się w narracji mojego klienta. Po prostu wszyscy to robimy (do czasu!) - jedni mniej, inni bardziej. Jednak każda prawniczka, każdy prawnik, część z tych błędów ma wpisane w swoje codzienne funkcjonowanie. Ten kto błądzi, rzadko to widzi. Być spojrzenie na kogoś innego, kto błądził, pomoże Ci zobaczysz własne błądzenie. Mnie te wszystkie „błędy” ciągle pchały do przodu, w kierunku życia takiego jakiego chcę - zdefiniowanego, a nie takiego, które było dziełem przypadku. Do takiego spojrzenia na błędy i porażki dziś Cię zapraszam.

Spółka? Really? - Dlaczego? - Po co? Od tego pewnie zacząłby Simon Sinek, gdybyśmy prowadzili konwersację na temat prawniczych spółek.Dziś o tym po co prawnicy wchodzą w spółki i jakie z tego mają korzyści (realne, ukryte, nieświadome). Jest też o iluzjach, którym ulegamy, gdy zawiązujemy spółki. Wiadomo - wyobraźnia i marzenia działają, ale jeśli za długo lata się w chmurach, a skrzydła poklejone są woskiem, można upaść z wysoka ... na - przysłowiowy - pysk (lub ryj). A to już naprawdę boli. Dlatego warto się urealniać i rzeczywiście, trzeźwo, rozsądnie i z rozmysłem patrzeć na rzeczy, gdy chce się "mieć spółę", być wspólnikiem. Sporo też mówię o typowych, spółkowych zgrzytach - tym co zatruwa chęć przyjścia do pracy i spotkania się z tym "wkurzającym" człowiekiem albo "drażniącym" zespołem. W tym odcinku jest przede wszystkim o:▪️powodach zawiązywania spółek▪️poziomach na których wspólnicy mogą (powinni?) się dogadywać, spotkać...▪️przyczynach, które sprawiają, że spółki "nie wychodzą" albo stają się koszmarem▪️o rozstaniach (wyjściach), które czasem są bardzo kulturalne, z czasem (z reguły?) niezbyt...Oczywiście nie sposób w godzinę opowiedzieć o wszystkim, dlatego traktuj proszę moje rozważania, jako część rzeczywistości, moje subiektywne jej postrzeganie. Ten temat to ogromna rzeka :) Zapraszam do słuchania i wspierania podcastu na patronite:https://patronite.pl/togabezwroga [Autopromocja] projektu "Toga bez wroga" Fundacji Alchemia Zmiany.#togabezwroga #świadomośćprawników #dobrostanprawnikow #coachingprawnika #mentoringprawnika #superwizjaprawnika

Staszek Soyka śpiewa, że cierpienie jest częścią szczęścia. Tak samo jest z kryzysem, który prowadzi do cierpienia. To może brzmieć dla Ciebie niedorzeczenie, nielogicznie… Ale… (jednak…) to kryzysy, które pojawiają się w prawniczym życiu prowadzą do najważniejszych zmian - do redefinicji patrzenia „na to, czy na tamto” - do odzyskania jakiegoś kawałka swojego życia i wzrostu, zwiększenia świadomości, uważności, obecności. Za tym z kolei idzie jakość bycia, życia, egzystencji, a tym samym dobrostan i szczęście. Zapraszam do 13. odcinka podcastu „Toga bez wroga” pt. „Prawnicze kryzysy”.Spowiadam się i opowiadam o własnych kryzysach, typowych ludzkich i prawniczych kryzysach. Jest o różnych rozczarowaniach, które dopadały mnie, koleżanki, kolegów, które dopadają też osoby, z którymi mam przyjemność pracować. Tłumaczę dlaczego kryzysy są tak ważne i jakie można z nich wyciągnąć lekcje. Przedstawiam różne rodzaje kryzysów na różnych etapach kariery. Jest też spory kawałek o kryzysie najważniejszym czyli Kryzysie Wieku Średniego  tzw. ciemnej nocy duszy :) No i opowiadam na wstępie o świadomych prawnikach na Instagramie, @uwaznyprawnik oraz #dobrostanprawników. Jeśli czujesz ten materiał, skomentuj, zrecenzuj, podziel się nim. Możesz też wesprzeć #togabezwroga na #patronite   

Czy timesheet to bullshit? Na to pytanie staram się - subiektywnie rzecz jasna - odpowiedzieć w 9. odcinku podcastu „Toga bez wroga”.Jestem zdania, że gdy nie nauczysz się cenić swojego czasu, nie będziesz dobrze zarabiać. Jeśli Twoja energia (czas) nie jest dla Ciebie cenna, to jak ma być cenna dla Twojego klienta, który ma za nią zapłacić? W odcinku dzielę się swoją wiedzą i doświadczeniem z zakresu rozliczeń, ryczałtów i ewidencjonowania czasu pracy.Jest o narzędziach, których używałem, trochę o metodach rozliczenia, jest też o tym co można rozliczyć i jak. Czarno na białym pokazuję, że brak wiedzy na temat swojego czasu pracy jest brakiem wiedzy na temat sytuacji finansowej prawnika, kancelarii i wydajności, efektywności zespołu. Posłuchasz też o uczciwości i transparentności w rozliczeniach, które gdy są zachowane, stają się Twoim sprzymierzeńcem we wszelkich wątpliwościach Twojego klienta. A jeśli dla Ciebie „timesheet to bullshit”, to być może fragment o przekonaniach prawników i niedogodnościach stosowania ryczałtów oderwanych o realiów czasowych Cię przekona do zmiany sposobu myślenia i funkcjonowania. Jak sądzisz, czy klient jest w stanie uwierzyć i zaufać prawnikowi, który nie jest pewny siebie, swoich kompetencji, a tym samym swojej stawki? Czy prawnik z wątpliwościami i niepewnością przyciąga klientów gotowych zapłacić godziwe wynagrodzenie? Zapraszam do słuchania, komentowania i recenzowania. Jeśli chcesz wesprzeć podcast i projekt #togabezwroga zapraszam na Patronite #patronite.Linki w komentarzu. I pamiętaj… ODPOCZNIJ :)[AUTOPROMOCJA]

Dzisiejszy odcinek specjalny jest o tym, jak mapuję proces pozyskiwania klienta w kancelarii (i wszędzie indziej, gdyż te rozważania dotyczą każdej branży)? Jakie ważne decyzje musisz podjąć na sam początek, jeśli chcesz pozyskać klienta/ów?Czy Twój sposób i pomysł na pozyskiwanie klienteli, uwzględnia to, jaka/-i jesteś, jaka jest Twoja natura, potrzeby, preferencje, to gdzie się zaczynasz, a gdzie kończysz (mówiąc metaforycznie)?Czy wiesz gdzie jest Twój potencjalny klient, gdzie go szukać, jak rozpoznać osobę decyzyjną i do niej dotrzeć? Czego ona potrzebuje i czy potrafisz jej to dać?A może jest coś co sprawia, że w ogóle nie musisz szukać klientów i ich pozyskiwać - czasem tak jest, u niektórych tak jest. O tym na sam koniec odcinka.Na powyższe pytania znajdziesz odpowiedź w styczniowym odcinku specjalnym podcastu Toga bez wroga dla Subskrybentek i Subskrybentów. Wjeżdża rzutem na taśmę 31 stycznia :)Subskrybentkom, subskrybentom, matronom i patronom serdecznie dziękuję za wsparcie fundacji i rozwoju projektu Toga bez wroga.KONICZNIE - PROSZĘ - ZAJRZYJ...→ do e-booka "Prawniku, wylicz stawkę!", z którego dowiesz się, jak policzyć stawkę, marżę, dobre życie, a przede wszystkim przestaniesz podcinać sobie skrzydła⁠https://prawnikuwyliczstawke.pl/⁠→ na warsztat z wyliczenia stawki (6 godzin, online, Zoom)⁠https://wyliczstawke.pl/⁠→ na Togę bez wroga, jeśli chcesz ze mną popracować solo lub w grupie.⁠https://togabezwroga.pl/oferta⁠→ na NIEODPŁATNĄ sesję wstępną:⁠https://calendly.com/togabezwroga/poznajmy-sie

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital and Chris O'Brien Lifehouse , leads a practical overview of managing thymic cancers in Australia and New Zealand. She is joined by an expert panel featuring Prof Steven Kao, a thoracic medical oncologist at Chris O'Brien Lifehouse, Dr. Felicity Meikle, a cardiothoracic surgeon at the Waikato District Health Board in Hamilton, and Dr. Dasantha Jayamanne, a radiation oncologist at Royal North Shore Hospital and Genesis Care in Sydney. Despite being a "forgotten area" in thoracic oncology, these rare tumours remain a key focus for research and multidisciplinary care. (00:00) Introducing the Topic and Experts (02:10) Epidemiology and Risk Factors (04:26) Symptoms and Initial Workup (06:40) PET Scans and Biopsy Decisions (11:40) Pathology and Staging Basics (15:05) MDT Strategy (16:08) Postoperative Treatment (19:46) Perioperative Systemic Therapy (23:08) Stage IV Management and Surgery (25:47) Immunotherapy in Thymic Carcinoma (34:51) Next Line and Targeted Options (42:04) Wrap Up and Thanks Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Arkadiusz Steć zaczynał od substytucji za 200 zł i kserokopii akt w NSA za 100 zł. Dziś prowadzi kancelarię, którą zbudował sam — bez reklam, bez agencji, bez zimnych maili. Na Facebooku, potem na LinkedInie i na newsletterze, który czytają głównie prawnicy.W tym odcinku rozmawiamy o tym, czym naprawdę jest mikrokancelaria. Nie jako kompromis, nie jako brak odwagi do skalowania — ale jako świadomy wybór. O tym, jak myśleć o wycenie, kiedy rezygnować z klientów i dlaczego gen wolności musi być w tobie silny, zanim w ogóle zaczniesz.Jest też matematyka: 64 godziny miesięcznie. Tyle możesz sprzedać jako solista. Pytanie tylko — za ile.Odcinek trwa ok. 75 minut.Gość odcinka: Arkadiusz StećAdwokat, autor e-booków o mikrokancelarii.

Solve crimes with the great detective in "Sherlock Holmes Short Stories." Featuring classic tales by Arthur Conan Doyle, this podcast brings you the brilliant deductions and thrilling adventures of Sherlock Holmes and Dr. Watson. Whether you're a longtime fan or new to the world of Holmes, these timeless mysteries will keep you captivated.

Spurs Chat: Discussing all Things Tottenham Hotspur: Hosted by Chris Cowlin: The Daily Tottenham/Spurs Podcast Hosted on Acast. See acast.com/privacy for more information.

In this episode of TOGA's 'Conversations in Lung Cancer Research,' A/Prof Mel Moore interviews A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health and Convenor at the 2026 TOGA ASM. They discuss his academic background, his unexpected journey into oncology, a fellowship in Boston and MBA in London and his vision for the future of lung cancer treatment. [0:00] Introduction [2:05] Career Foundations [3:19] Choosing Oncology  [6:39] Translational PhD  [12:00] Finding the Balance  [13:36] The Boston Fellowship [18:00] The MBA Journey in London [25:35] Targeted Therapies + SCLC [30:10] Convening the TOGA ASM [32:53] Future Ambitions Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Cadaver_In_Roman_Toga

In dieser Folge von Zwei Doofe, eine Tanke stürzen sich Wenzel und Olumbo kopfüber in die Welt der Schickeria, prangern die Münchener Bierzelt-Dekadenz an und beenden die Episode mit einem mittelscharfen Körperverletzungsversuch. Hier sind die Highlights aus dem Ozean der Ignoranz:Wal-Update – Timmy auf der "Bartsche": Der gestrandete Wal wurde in ein maßgeschneidertes Gestell (von Wenzel liebevoll "Bartsche" genannt) verfrachtet und schippert nun mitsamt pulsierendem Herzen Richtung Atlantik. Olumbo hat vom maritimen Mitleid allerdings längst die Nase voll und zitiert stattdessen eiskalte Kalendersprüche: "Mitleid kriegst du geschenkt, Neid musst du dir erarbeiten".Dekadenz im Weinzelt & das Champagner-Verbot: Ein nostalgischer Rant führt die beiden ins Kufler Weinzelt auf dem Oktoberfest. Die völlig absurde Tradition, dass Reiche riesige Champagner-Flaschen kaufen, sie nicht trinken, sondern auf den mit Regenschirmen bewaffneten Pöbel spritzen, soll durch den neuen Bürgermeister Dominik endlich abgeschafft werden. Das Motto dieser feucht-fröhlichen Unterdrückung lautet treffend: "Eure Armut kotzt mich an".Gunter Sachs und der goldene FKK-Kelch: Eine Zeitreise nach St. Tropez und an die Nacktbadestrände von Sylt bringt alte Playboy-Geschichten zutage. Gunter Sachs flanierte dort einst in einer weißen Toga und mit einem goldenen Kelch in der Hand in einer V-Formation durch die ahnungslosen Nackten.Der Ritterschlag zum "Chevalier de Moutard": Der beste Prank der 60er Jahre: Um spießige deutsche Touristen bloßzustellen, stahl Sachs ein Senftöpfchen, klatschte den Opfern feierlich zwei Löffel Senf auf die Schultern und schlug sie unter Applaus des ganzen Ladens zum "Chevalier de Moutard" (Fürst des Senfes).Die mittelscharfe Studio-Attacke: Da die obligatorische Dienstagswurst ausfällt, plant Olumbo einen gigantischen Fleisch-Exzess beim Lieblingsgriechen "Kalypso". Doch bevor er das Studio verlassen kann, holt Wenzel heimtückisch die Senftube aus der letzten Folge hervor, um Olumbo gegen seinen Willen zum "Chevalier de Moutard" zu krönen – woraufhin dieser entsetzt Reißaus nimmt. Hosted on Acast. See acast.com/privacy for more information.

Existe um momento em que a justiça deixa de ser princípio… e vira ritual. Neste episódio, partindo da queda de Harvey Dent em The Dark Knight, mergulhamos numa pergunta incômoda: o que acontece quando quem julga abandona o critério e passa a decidir por narrativa, convicção ou conveniência? Sem caricaturas, exploramos as lentes que moldam decisões sob poder, do cinismo ao fanatismo, da vaidade à desumanização, para entender onde termina a lei… e começa o homem por trás da toga. See omnystudio.com/listener for privacy information.

Der Release des großen Vulkan-DLCs für Anno 117 ist geplatzt! Ubisoft zog in allerletzter Sekunde die Notbremse, denn ein kritischer Bug drohte, unsere hunderte Stunden alten Savegames zu zerstören. Zusammen mit Strategie-Experte Writing Bull atmen wir kurz auf, denn die Verschiebung war die absolut richtige Entscheidung. Doch danach machen wir den großen Reality-Check ohne rosarote Brille: Wo steht Anno 117 knapp ein halbes Jahr nach Release wirklich? Wir diskutieren über Ubisofts kurioses Planungs-Chaos (Hallo, Heroes of Might & Magic!), den dringend nötigen Nerf des übermächtigen Passivhandels mit Update 1.5 und klären die wichtigste Frage: Ist das Aufbau-Epos jetzt endlich in dem Zustand, den wir uns gewünscht haben? Schnappt euch eure Toga, lehnt euch zurück und diskutiert mit: Seid ihr froh über die Notbremse oder einfach nur genervt vom Hin und Her? Alle Links zum GameStar Podcast und unseren Werbepartnern: https://linktr.ee/gamestarpodcast

Editorial: Escravos de toga

Kancelaria, która zarabia. Nie jako slogan. Jako konkretna decyzja o tym, co chcesz robić, z kim i za ile.Kamila Kurkowska przyszła z e-bookiem pod pachą i bez zamiaru owijania w bawełnę. Rozmawiamy o tym, dlaczego prawnicy boją się podnosić stawki, dlaczego obsługują klientów, których nie chcą, i dlaczego kancelaria to firma — jak warzywniak albo gabinet kosmetyczny — i z tym trzeba się pogodzić.Jest też o pokoleniu, które wchodzi do zawodu z obietnicą, która nie działa. O tym, że sukcesy warto celebrować zamiast gonić za kolejnymi. I o tym, że nierentowny klient to nie tylko kwestia finansów — to też koszty emocjonalne, których się nie wyliczy.Odcinek trwa ok. 75 minut.Gość odcinka: Kamila KurkowskaDoradczyni i mentorka biznesowa dla prawników i prawniczek. Autorka e-booka Kancelaria, która zarabia. Tom I.

In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Surein Arulananda (Medical Oncologist, Monash Health) is joined by members of the Local Organising Committee to provide an exclusive preview of the 2026 TOGA Annual Scientific Meeting (ASM). The panel discusses the most anticipated sessions, emerging themes in thoracic oncology, and the evolving landscape of lung cancer care in Australia and New Zealand. (00:00) Welcome and Acknowledgement (00:40) Meet the Panel (01:21) Nursing Priorities (02:09) Precision Survivorship (03:25) Respiratory Viewpoint (05:22) Nodule Management (06:46) Radiation Oncology Sessions (09:22) Must See Immunotherapy (11:42) Small Cell Spotlight (12:45) One Session for Everyone (14:45) Debates and AI (17:30) Closing Thanks Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

The_Cadaver_in_the_Roman_Toga

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including: A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA Key ongoing trials of HER2-directed therapies in BTC and GEA Presenters:  Amit Mahipal, MD, MPH Chief, GI Medical Oncology Program Professor of Medicine Ruth and Goodman Endowed Chair in GI Oncology H Seidman Cancer Center and Case Western Reserve University Cleveland, Ohio Shubham Pant, MD Professor Department of Gastrointestinal Medical Oncology Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center Houston, Texas Link to full program:https://bit.ly/4ckcBrZ Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually. (00:00) Welcome and Acknowledgement (00:43) Meet the Expert Guests (01:40) ALK History and Breakthroughs (03:48) Who Gets ALK Lung Cancer (04:57) Workup and Staging Essentials (05:54) Patterns of Spread and Clots (07:24) Second Generation TKIs Standard (09:03) Long Term Toxicities (11:07) Progression Assessment and LAT (12:50) Lorlatinib After Progression (15:46) Lorlatinib First Line Crown Data (17:11) Choosing and Dosing Lorlatinib (20:55) Managing Lorlatinib Side Effects (22:29) Predicting Response and Follow Up (29:30) Next Generation Inhibitors NAL (32:04) Early Stage and Adjuvant TKIs (36:32) Beyond TKIs Chemo and ADCs (39:30) Patient Support and Closing Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the current treatment landscape for frontline HER2-positive gastroesophageal junction (GEJ) and gastric cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we welcome Dr. Sunnie Kim from the University of Colorado and Dr. Samuel Cytryn from Memorial Sloan Kettering, who shared their insights on the latest advancements in HER2-targeted therapies. We discussed the pivotal TOGA and KEYNOTE-811, the promising data from the HERIZON-GEA01 study featuring Zanidatamab, and the implications of these findings for clinical practice. Key topics included: Current standard of care for HER2-positive GEJ and gastric cancer The role of PD-L1 status in treatment decisions Mechanisms and efficacy of Zanidatamab compared to traditional therapies Management of side effects, including diarrhea and infusion-related reactions Future directions in HER2-targeted therapies, including T-DXd based on the DESTINY Gastric-04 trial Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/new-precision-strategies-for-her2-gea-interpreting-new-data-to-inform-clinical-practice

Shot of Nostalgia: Shuffle continues with your host Acefield Retro, and this week we revisit April 4, 1993, WrestleMania IX from Caesars Palace in Paradise, Nevada. The first fully outdoor WrestleMania. The World's Largest Toga Party. A Roman coliseum theme complete with live animals, trumpeters, and commentators fully committed to the presentation. But beyond the spectacle, this event represents a pivot. This episode traces the road into WrestleMania IX through the March and April 1993 Wrestling Observer Newsletter coverage, capturing a company navigating lawsuits, scrutiny, roster instability, and mounting pressure. Bret Hart entered as WWF Champion. Yokozuna had been elevated as the dominant Royal Rumble winner. Hulk Hogan had returned, but his long term direction was fluid rather than locked in. The structure of the card reflects that instability. Shawn Michaels versus Tatanka opens with an Intercontinental Championship match that creates movement without definitive closure, immediately signaling protection over payoff. The Steiner Brothers versus the Headshrinkers provide one of the night's most cohesive in ring performances, reinforcing how effective the tag division could be when execution was clean. Doink versus Crush leans heavily into character psychology and spectacle, highlighted by the double Doink finish. We examine the originally planned mechanical stunt that was scrapped and what that decision says about the era's emphasis on visual moments. Razor Ramon secures a direct win over Bob Backlund, continuing his steady rise. The Tag Team Championship match between Money Inc. and the Mega Maniacs unfolds through referee bumps, disqualification tension, and spectacle driven pacing. We revisit the reported late reshuffling that removed the originally planned tag title blow off and centered Hogan more prominently on the card. Lex Luger's WrestleMania debut against Mr. Perfect introduces rope leverage controversy and is layered with behind the scenes anecdotes that contribute to the uneven rhythm of the night. The Undertaker versus Giant Gonzalez becomes one of the most criticized finishes in WrestleMania history, prioritizing theatricality over decisive resolution. The championship picture ultimately defines the event. Bret Hart versus Yokozuna is framed as a generational collision until Mr. Fuji's salt interference shifts the WWF Championship. Moments later, Hulk Hogan enters, accepts an impromptu challenge, and captures the title in approximately twenty seconds. With three decades of hindsight, this episode examines whether that closing decision reflects creative confusion or calculated business pragmatism. The Observer context suggests urgency. The optics suggest an audible. The result reshaped Bret Hart's reign, altered Yokozuna's trajectory, and placed Hogan back on top during a volatile moment for the company. WrestleMania IX is remembered for its ending. It deserves to be studied for what it reveals about transition, pressure, and how quickly direction can change when stability becomes the priority. Shot of Nostalgia: Shuffle premieres Saturday wherever you listen. Like, subscribe, and leave a review to support the continued growth of the series. Visit TurnbuckleTavern.com for merchandise, archives, and the full network schedule. Support the project at Patreon.com/TheTurnbuckleTavern for exclusive content and extended deep dives. Powered by G FUEL and Dick Lazers. Use code TAVERN at checkout to save twenty percent on your entire order.  

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Antonio Settembre"La toga spezzata"Viaggio nel Processo Penale e nella Riforma che cambia la Magistratura.Distribuzione: www.amazon.itUn viaggio chiaro e coinvolgente dentro i meccanismi del processo penale, per orientarsi tra regole, ruoli e recenti riforme. Scopri cosa cambia con la riforma della separazione dellecarriere e perché riguarda da vicino anche te.Durante la sua carriera, l'autore ha trattato – come relatore ed estensore della sentenza – numerosi processi importanti, tra cui la strage dei Georgofili a Firenze, del 1993, e tutte quellecollegate di via Palestro a Milano, di via Fauro a Roma, di San Giovanni in Laterano e di San Giorgio al Velabro, anch'esse commesse a Roma, oltre, ovviamente, a numerosissime altrevicende giudiziarie, soprattutto in materia fallimentare. Oggi ci racconta, attraverso la sua esperienza professionale, la complessa macchina della giurisdizione italiana, civile e penale, per arrivare a sviscerare il processo penale e comprendere i punti più cruciali del Referendum di giustizia del 22 e 23 marzo 2026."Il processo penale italiano è una delle costruzioni giuridiche più sconosciute al cittadino medio. Sebbene la sua rilevanza sociale e il suo impatto sulla vita delle persone siano estremamente significativi, la conoscenza dei meccanismi che presiedono al funzionamento del processo risulta appannaggio di pochi; in pratica, dei soli operatori giuridici - magistrati e avvocati penalisti - impegnati nella gestione dei processi.L'ambizione di questo scritto è, innanzitutto, quella di fornire, ai non addetti ai lavori, nella maniera più semplice e obbiettiva possibile, le cognizioni minime atte a comprendere qual è la struttura del procedimento penale, come nasce e come evolve e quali sono i soggetti che si muovono nell'ambito dello stesso. Ciò verrà fatto con l'utilizzo di un linguaggio non tecnico, o minimamente tecnico, per estendere al massimo la platea dei possibili fruitori di questo scritto.Non è dubitabile che la conoscenza del sistema giudiziario (riferita, quantomeno, al sistema penale) non solo aiuterà a comprendere l'evoluzione di moltissime vicende giudiziarie dell'attualità, ma può contribuire alla formazione di un giudizio più consapevole sulle infinite questioni che agitano il mondo della giustizia, squassato, come pochi altri, dalle polemiche e dalla disinformazione."Antonio Settembre nasce a Salerno nel 1955. Ha iniziato a lavorare in magistratura come pretore a Cagliari nel 1986. Successivamente, da 1991 al 1996, ha lavorato come sostitutoprocuratore a Lucca, poi giudice a Firenze dal 1996 al 2012. Fino al 2021 è stato consigliere della Corte suprema di cassazione e fino alla pensione nel 2025, Presidente di sezione della Corte d'appello di Firenze.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

Solve crimes with the great detective in "Sherlock Holmes Short Stories." Featuring classic tales by Arthur Conan Doyle, this podcast brings you the brilliant deductions and thrilling adventures of Sherlock Holmes and Dr. Watson. Whether you're a longtime fan or new to the world of Holmes, these timeless mysteries will keep you captivated.

Crônicas da Cidade - 16/01

La reforma judicial de 2024 marca una nueva etapa para la justicia en México. Las y los jueces electos por voto popular están ya en funciones

It's our year-in-review fashion and culture edition. I'm joined by new Ground Pass contributor Kaya Courtside to break down the exhibition season and what it's really like covering tennis behind the scenes, from UTS Finals in London to the chaos and charm of these off-season events. Then I hand out my 2025 tennis style “awards,” from best dressed and outfit of the year to the meme moments that took over our feeds. Plus, quick tennis news: the WTA's Mercedes-Benz era begins in 2026, Garbiñe Muguruza joins Madrid's leadership team, Serena's testing-pool headline sparks speculation, and Next Gen is around the corner. 00:00 Introduction to the Year in Review03:12 Introducing Kaya Courtside and UTS Finals30:10 Exhibition Season and Upcoming Events31:03 Fashion and Style Awards of 202536:11 Outfit of the Year and Brand Partnerships41:58 Cultural Moments and Player Highlights45:29 Tennis Photos and Memes of the Year51:31 Most Stylish Tournament and Personality of the Year58:52 WTA News and Future Predictions01:04:44 Upcoming Projects and Wrap-UpLinks:- GP Exhibition Deep Dive Episode - https://youtu.be/fjuxg3dzIXs?si=raOH2B8XOMWO7wrD - The Real Challenger Documentary - https://youtu.be/fjuxg3dzIXs?si=raOH2B8XOMWO7wrD - Off Season Instagram - https://www.instagram.com/offseasontv?igsh=MWJhaHZ4ano4NWlpeQ%3D%3D&utm_source=qr - Off Season Tiktok - We have Merch!!! Ground Pass Shop - https://www.groundpasspodcast.com/ground-pass-shop

This episode was presented by UJA. Support UJA's work at UJA.orgSubscribe to Inside Call me Back: inside.arkmedia.org/?utm_source=shownotes&utm_medium=podcast&utm_campaign=insideGift a subscription of Inside Call me Back: inside.arkmedia.org/giftsListen to What's Your Number: lnk.to/GsOESPSubscribe to Amit Segal's newsletter ‘It's Noon in Israel':arkmedia.org/amitsegal/Watch Call me Back on YouTube: youtube.com/@CallMeBackPodcastCheck out Ark Media's other podcasts: For Heaven's Sake: https://lnk.to/rfGlrA‘What's Your Number?': https://lnk.to/rfGlrAFor sponsorship inquiries, please contact: callmeback@arkmedia.orgTo contact us, sign up for updates, and access transcripts, visit: arkmedia.org/Ark Media on Instagram: instagram.com/arkmediaorgDan on X: x.com/dansenorDan on Instagram: instagram.com/dansenorTo order Dan Senor & Saul Singer's book, The Genius of Israel: tinyurl.com/bdeyjsdnToday's Episode: We are less than a week away from the beginning of Hanukkah. Keeping with recent Call me Back tradition, Dan was joined by Rachel Goldberg-Polin to discuss the timeless meaning of the Hanukkah story. What does it say about the conflict Jews face today? Can the few really defeat the many? And why are Jews so obsessed with counting?CREDITS:ILAN BENATAR - Producer & EditorADAAM JAMES LEVIN-AREDDY - Executive ProducerBRITTANY COHEN - Production ManagerMARTIN HUERGO - Sound EditorMARIANGELES BURGOS AND PATTRICIO SPADAVECCIA - Additional EditingMAYA RACKOFF - Associate ProducerGABE SILVERSTEIN - Community ManagementYUVAL SEMO - Music Composer

We are less than a week away from the beginning of Hanukkah. Keeping with recent Call me Back tradition, Dan is joined by Rachel Goldberg-Polin to discuss the timeless meaning of the Hanukkah story. What does it say about the conflict Jews face today? Can the few really defeat the many? And why are Jews […]

Samfylkingin í Reykjavík stendur á krossgötum. Hún þarf að velja sér leiðtoga í höfuðborginni í fyrsta skipti í nærri tuttugu ár. Forsætisráðherra vill halda þar völdum og er sögð vera á höttunum eftir nýjum oddvita. Það bar til í liðinni viku, undan Senegalströndum, að ráðist var á tyrkneska olíuskipið Mersin, líklega með sprengjudrónum. Skipið er í eigu tyrknesku útgerðarinnar Besiktas shipping en siglir undir fána Panama - og er talið tilheyra hinum svokallaða skuggaflota Rússa. Úkraínumenn hafa ekki gengist við árásinni en árásum af þessu tagi hefur fjölgað og þær eru taldar á gráu svæði. Á miðvikudaginn (10. desember) tekur bann við samfélagsmiðlanotkun barna undir sextán ára gildi í Ástralíu og varðar háum sektum ef fyrirtæki ganga ekki fram í að koma í veg fyrir að ungmenni komist á miðlana.

If movies like Animal House, Legally Blonde, and The House Bunny shaped your Greek life dreams… brace yourself. Greek life isn’t what Hollywood promises.See omnystudio.com/listener for privacy information.

If movies like Animal House, Legally Blonde, and The House Bunny shaped your Greek life dreams… brace yourself. Greek life isn’t what Hollywood promises.See omnystudio.com/listener for privacy information.

Nur ein Anno mit Toga? Wir diskutieren die historische Korrektheit von Anno 117: Pax Romana mit Micha, der Archäologin Michaela Zietlow und Strategie-Experten Gaius. Logistik, Kultur und das finale GameStar-Urteil!

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:Brief overview of BTC and GEAApproved HER2-directed therapies for BTC and GEA and their mechanisms of actionEfficacy and toxicities of the approved agents and optimal management strategiesKey ongoing trials of HER2-directed therapies in BTC and GEAChallenges faced by healthcare professionals in the management of patients with BTC and/or GEA PresentersAmit Mahipal, MD, MPHDirector, Gastrointestinal Medical Oncology ProgramRuth and Donald Goodman Endowed Chair in GI OncologyProfessor of Medicine, Senior Attending PhysicianUniversity Hospitals Siedman Cancer CenterCase Comprehensive Cancer CenterCase Western Reserve UniversityCleveland, OhioShubham Pant, MDProfessorDepartment of Gastrointestinal (GI) Medical OncologyDepartment of Investigational Cancer TherapeuticsDirector of Clinical ResearchAssociate Director for Early Phase Drug DevelopmentSheikh Ahmed Bin Zayed Al Nahyan CenterMD Anderson Cancer CenterHouston, TexasLink to full program:https://bit.ly/3KL2ank Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bogi Ágústsson og Þórunn Elísabet Bogadóttir ræddu fundahöld evrópskra leiðtoga í Kaupmannahöfn um fjölþáttaógnina frá Rússum. Leiðtogar Evrópusambandsins þinguðu í gær og í dag bætast fleiri evrópskir leiðtogar í hópinn, þar á meðal Kristrún Frostadóttir forsætisráðherra Íslands. Þá var einnig rætt um úrslit kosninga í Moldóvu þar sem PAS-flokkurinn (Aðgerðir og samstaða), fékk meirihluta þingsæta. PAS vill náið samstarf við Vesturlönd og inngöngu í Evrópusambandið.

We're wrapping up 1 & 2 Peter with quizzes written by our listeners!If you want MORE drinking and bible-ing, including bonus episodes, interviews with experts, fun mini series', and more, consider becoming a ‘parishioner' at Patreon.com/DrunkBibleStudyOur theme music is Book Club by Josh and Anand.

Put on your best toga and come party with the variants as we review Annabelle's Trust Me You'll Like It - Animal House!! TOGA, TOGA, TOGAPlease leave us a 5 star review on your podcast platform, drop us a follow on the socials, consider joining the Patreon, & share with your friends & family! Thank you for listening & thank you for all the support! Links for all of our stuff can be found here: https://linktr.ee/VariantVendettaYou can find our good friend's Podcasts here:https://www.abingerspodcast.com/https://linktr.ee/goingmerrypod

When I first connected with Jason Trew (callsign: TOGA), I knew this conversation would challenge some assumptions about where design thinking belongs. Jason is an Air Force fighter pilot and strategy leader turned professor. What emerged from our conversation wasn't just another story about design thinking adoption, but a deeper exploration of what he sees happening when we distinguish between capital-D Design Thinking and lowercase-d design thinking, and why that distinction matters for everyone trying to create meaningful change. Jason's journey from F-15 pilot to design educator reveals something crucial about how design thinking transforms not just what we do, but who we become as problem solvers. His work with thousands of Air Force officers, his deployment experiences in classified operations centers, and his current role (*at the time of recording) teaching at the Savannah College of Art and Design (SCAD) offer unique insights into how design thinking functions when the stakes are genuinely high. Listen to Learn About: What's the critical difference between capital-D Design Thinking and lowercase-d design thinking, and why does this distinction matter for practitioners? How can design thinking principles function effectively in highly structured, high-stakes environments where traditional approaches dominate? What role does psychological safety ("feeling safe, supported, and stretched in meaningful ways") play in enabling creative problem-solving? How do we balance the need for systematic approaches with the emergent, integrative nature of actual design work? When should leaders prioritize conditioning people into a "ready stance" versus teaching specific design methods? Our Guest Col Jason "TOGA" Trew (US Air Force, retired) represents a fascinating intersection of military leadership, academic rigor, and design practice. After graduating from the U.S. Air Force Academy and flying F-15s, Jason spent his final military decade revolutionizing how the Air Force approaches strategy education and leadership development. He earned a PhD in the history of technology, served as Dean and Vice Commandant of the Air Force Leadership School, and led design teams for Space Force education initiatives. Now a Professor of Design* Management at the Savannah College of Art and Design, Jason brings a unique perspective on what happens when design thinking meets organizational realities where failure isn't an option. (*At the time of recording.) Episode Highlights [02:10] Jason's journey from F-15 fighter pilot to design educator through strategy school and a PhD in technology history [03:30] Discovery of a book dedicated to Icarus as hero rather than cautionary tale, sparking interest in playfulness complementing practicality [04:20] How design thinking became curriculum at Air Force Leadership School serving 4,000 students annually [05:10] Jason's certification in Lego Serious Play for facilitating innovation sprints and strategic thinking workshops [07:20] The crucial distinction between capital-D Design Thinking and lowercase-d design thinking [09:00] Capital-D focuses on activities and checklists; lowercase-d develops embodied sensibility for knowing what to do next [11:40] Design thinking as conditioning people into a ready stance for handling surprise rather than teaching linear processes [13:00] Why Jason believes design thinking changes the people involved, with problem-solving as bonus rather than primary goal [14:40] How design thinking shifts perception to see multiple options beyond binary choices [15:30] Jason's approach to ambiguous assignments that allows students to surprise him with creative solutions [17:30] Learning design principles that avoid constraining student intelligence for the sake of rigid academic standards [18:50] Design thinking's spillover effects on leadership and education beyond formal design practice [22:40] Design thinking as fundamentally human activity connected to living well and building better communities [25:10] Coffee shop door story illustrating how design changes your eyes to see problems everywhere [26:40] Design as integrative discipline that's undisciplined in the best academic sense [28:40] Framework of design as expedient - practical, opportunistic, and contextual rather than optimal [30:00] Why expedient design requires ethical sensibility to guide this human superpower responsibly [32:30] Jason's faith that if we designed current systems, we can design something better [36:40] Deployment story of creating psychological safety in classified military operations center [38:30] Using Lego as thermoplastic polymer strategic thinking tool to overcome initial skepticism [39:00] Daily check-ins asking team members if they feel safe, supported, and stretched in meaningful ways [41:10] Danger of treating organizational roles as reality rather than abstractions of actual people [43:30] Failed redesign of Air Force Leadership School and lessons about empathy work threading through entire processes [46:00] Dawan's diagnostic questions about organizational readiness and past innovation attempts [48:30] Strategy for identifying key voices—influencers, critics, curmudgeons, and creators—in organizations [49:00] Power of storytelling as diagnostic tool and method for strategic thinking [50:40] Interest in story casting and narrative intelligence using physical artifacts like Lego Serious Play [51:00] Connection to UN Principles for Responsible Management Education and sustainable development goals [52:40] Jason's call for partnership in bringing design skills to local and systemic governance challenges Questions to Help You Go Deeper Learning What surprised you most about Jason's distinction between capital-D and lowercase-d design thinking, and how does this change your understanding of design thinking's role in organizations? Which aspects of Jason's "expedient" framework for design seem most valuable for your context — the practical, opportunistic, or contextual elements? How does Jason's experience with ambiguous assignments challenge your current approach to giving direction or defining success criteria? Leading Where in your organization would Jason's "safe, supported, and stretched in meaningful ways" framework create the most value for team performance? How might you help your team understand the difference between learning design methods and developing a design sensibility? What would success look like if you implemented Jason's approach to activating the full diversity already present in your team? Applying What's one small experiment you could run next week with leaving an assignment or challenge more open-ended? Which current organizational challenge could you address by focusing on conditioning people's "ready stance" rather than teaching them specific methods? How could you adapt Jason's storytelling diagnostic approach to better understand your team's readiness for change? Practicing How will you build the habit of distinguishing between roles/responsibilities (abstractions) and the full capabilities of people in those roles? What support or resources do you need to practice Jason's approach of setting conditions rather than controlling outcomes? Who could you partner with to practice the kind of empathy work Jason describes as threading through entire processes? Resources Books We Discussed Experiencing Design - Jason's top recommendation for understanding how activities yield experiences that yield ways of being in the world. Liedtka, Jeanne, Karen Hold, and Jessica Eldridge. Experiencing Design: The Innovator's Journey. Columbia Business School Publishing, 2021. Creating Wicked Students - About giving students practice with authority and ambiguity in classroom settings. Hanstedt, Paul. Creating Wicked Students: Designing Courses for a Complex World. Stylus Publishing, 2018. Tools We DiscussedLego Serious Play - Certification and facilitation methods for strategic thinking workshops The Archipelago of Design - Security professionals using design approaches.  COM-B Behavior Change Model - Capability, Opportunity, Motivation framework for behavior change. Michie, Susan, et al. "The Behaviour Change Wheel: A New Method for Characterising and Designing Behaviour Change Interventions." Implementation Science, vol. 6, no. 1, 2011, pp. 1-12. Keep LearningResearch Nigel Cross and Bryan Lawson's work on how designers think.  Cross, Nigel. Design Thinking: Understanding How Designers Think and Work. Academic Press, 2011. Lawson, Bryan. How Designers Think: The Design Process Demystified. 4th ed., Architectural Press, 2005. Explore participatory design and co-creation methodologies. Schuler, Douglas, and Aki Namioka, editors. Participatory Design: Principles and Practices. Lawrence Erlbaum Associates, 1993. Simonsen, Jesper, and Toni Robertson, editors. Routledge International Handbook of Participatory Design. Routledge, 2013. Investigate narrative intelligence Mateas, Michael, and Phoebe Sengers, editors. Narrative Intelligence. John Benjamins Publishing Company, 2003. (Advances in Consciousness Research, vol. 46) UN Principles for Responsible Management Education and sustainable development goals. United Nations Global Compact. Principles for Responsible Management Education. UN Global Compact Office, 2007. Deepen Your Learning Design Council UK + Systemic Design + Design in Government with Cat Drew — DT101 E78 Complements Jason's insights about bringing design to structured environments Cognitive Bias + Ethics + Dreaming the Future of Design with David Dylan Thomas — DT101 E112 Works with this episode to understand different approaches to design education Instructional Design + Adult Learning Experiences with Holly Owens — DT101 E134 Builds on Jason's themes about creating conditions for creative problem-solving

Federico anima a ir mañana sábado a la movilización de jueces y Fiscales frente al Supremo. Con Vanessa Vallecillo y Sergio Heras.